

leaders in the field and have identified several of the key enzymes involved in regulating chromatin structure. Professor Workman played a key role in the Iressa drug discovery programme at AstraZeneca and is now the Director of the Centre for Cancer Therapeutics at the Institute of Cancer Research UK. Through agreements with the Institute of Cancer Research (ICR) and University of Cambridge, and with Cancer Research Technology Ltd, Chroma has exclusive rights to the present and future research of its two UK-based founders. A similar arrangement with the University of Virginia has allowed Chroma to license key historical patents from the laboratory of David Allis.

The Company has raised seed financing from Abingworth Management and Cancer Research Technology and, in May 2004, raised £10 million in a series B financing led by the Wellcome Trust with participation from Gilde Investment Management and founding investor Abingworth.

More information about Chroma can be found at www.chromatherapeutics.com.